leisure time -WSS

leisure time

author：hotspot 2025-09-01 15:18:55 - browse：22

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Prime Medicine, Myeloid Therapeutics clash over genome

Wikipedia

focus

WSS

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

How to protect coverage of PrEP

How a key Senate committee is planning to regulate PBMs

Prime Medicine, Myeloid Therapeutics clash over genome

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Keeping primary care docs in field isn't impossible, says AAFP CEO

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Bright Health sells Medicare Advantage business to Molina

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

In age of alternative facts, a scholarly course on calling out crap

How to keep neuroscience’s past racism from being its future

Supreme Court strikes down use of affirmative action

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Cancer drug shortages should be causing more outrage

Christmas in the PICU brings some surprising joy

focus

Medicare drug price negotiation hasn't dried up venture capital

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Men with early prostate cancer can safely opt out of treatment

Severe heat forecast: Where scorching temperatures will persist over the next week

Editas, Vertex strike deal on CRISPR

Sophia Smith scores twice for US in in 3

knowledge

Wikipedia

focus

explore